I.YU. NIKULIN¹, A.E. BAGRIY², E.S. MIKHAILICHENKO², E.A. PYLAEVA², YA.A. SOVPEL²

 ¹Donetsk Clinical Territorial Medical Association, Donetsk, Donetsk People’s Republic

²M. Gorky Donetsk State Medical University, Donetsk, Donetsk People’s Republic

Contact details:

Mykhailichenko E.S. — Ph. D. (Medicine), Assistant Professor of the Department of Internal Diseases No. 2

Address: 16 prospekt Ilyicha, Donetsk, Donetsk People’s Republic, Russian Federation, 283003, tel.: +7-949-470-68-08, e-mail: klassiki@inbox.ru

Pancreatogenic diabetes mellitus (DM-P) is a topical multidisciplinary problem, many aspects of which need further research.

The purpose is to study the efficacy and safety of metformin as a component of hypoglycemic therapy in patients with DM–P in prospective follow-up.

Material and methods. The study included 81 patients with DM-P aged 54.7 (9.3) years, with a history of pancreatic lesions from 5 months to 4.5 years. In group A (n = 37), insulin preparations were used as hypoglycemic agents, in group B (n = 44) metformin (at HbA1c levels > 8% and fasting glycemia > 10 mmol/l insulin preparations were added to it). The follow-up was 10.6 (2.7) months.

Results. Initially, hypoglycemic treatment as metformin monotherapy was prescribed to 43.1% patients of group B, that insured adequate glycemic control in 27.3% of cases. During treatment, the average HbA1c levels decreased in group A from 9.8 (1.9) % to 8.6 (1.6) %, in group B — from 9.4 (1.8) % to 8.1 (1.4) %, respectively, p < 0.05. In group B, the proportion of people who achieved the target levels of HbA1c was significantly higher (61.3%) than in group A (35.1%), p < 0.05. The addition of metformin to insulin preparations in group B allowed reducing the insulin dose by ≥ 20% in 36% of patients. The treatment tolerability in both groups was satisfactory. The development of episodes of grade 1–2 hypoglycemia was noted in 20 (54.0%) and 18 (40.9%) patients in groups A and B; grade 3 — in 6 (16.2%) and 6 (13.6%), respectively, p > 0.05. The development of gastrointestinal effects of metformin was noted in 29.5% of patients and was transient.

Conclusions. The use of metformin in DM-P as monotherapy or in combination with insulin preparations was satisfactorily tolerated, contributed to improved glycemic control, allowed reducing insulin doses, and was associated with a decrease of pancreatitis recurrence.

Key words: diabetes mellitus, pancreatogenic diabetes mellitus, pancreatitis, metformin, insulin.

REFERENCES

1. Dedov I.I., Shestakova M.V., Vikulova O.K. et al. Epidemiological characteristics of diabetes mellitus in the Russian Federation: clinical and statistical analysis according to the diabetes mellitus register as of 01.01. 2021. Sakharnyy diabet, 2021, vol. 24, no. 3, pp. 204–221 (in Russ.).
2. American Diabetes Association. ADA Standards of Medical Care in Diabetes- 2023. Diabetes Care, 2023, vol. 46 (1), pp. S1–S291.
3. Bhattamisra S.K., Siang T.C., Rong C.Y. et al. Type-3c diabetes mellitus, diabetes of exocrine pancreas-an update. Current diabetes reviews, 2019, vol. 15 (5), pp. 382–394. DOI: 10.2174/1573399815666190115145702
4. Bradley D.A., Hart P.A. Diabetes Mellitus Related to Diseases of the Exocrine Pancreas (Pancreatogenic Diabetes) Diagnosis and Treatment. Clinical Pancreatology for Practising Gastroenterologists and Surgeons, 2021, pp. 668–678. DOI: 10.1002/9781119570097.ch80
5. Olesen S.S., Toledo F. G.S. et al. The spectrum of diabetes in acute and chronic pancreatitis. Current opinion in gastroenterology, 2022, vol. 38 (5), pp. 509–515. DOI: 10.1097/MOG.0000000000000864
6. Zhi M., Zhu X., Lugea A. et al. Incidence of new onset diabetes mellitus secondary to acute pancreatitis: a systematic review and meta-analysis. Frontiers in physiology, 2019, vol. 10, p. 637. DOI: 10.3389/fphys.2019.00637
7. Hart P.A., Bradley D., Conwell D.L. et al. Diabetes following acute pancreatitis. The Lancet Gastroenterology & Hepatology, 2021, vol. 6 (8), pp. 668–675. DOI: 10.1016/S2468-1253(21)00019-4
8. Dedov I.I., Shestakova M.V., Mayorov A.Yu. et al. Type 2 diabetes mellitus in adults. Clinical Recommendations. Sakharnyy diabet, 2020, vol. 23, no. S2, pp. 4–102 (in Russ.).
9. Ignatenko G.A., Bagriy A.E., Oprishchenko A.A. Sakharnyy diabet: rukovodstvo dlya vrachey [Diabetes mellitus: a guide for doctors]. Donetsk: RB Pozitiv, 2022. 640 p.
10. Valdez-Hernández P., Pérez-Díaz I., Soriano-Rios A. et al. Pancreatogenic diabetes, 2 onset forms and lack of metabolic syndrome components differentiate it from type 2 diabetes. Pancreas, 2021, vol. 50 (10), pp. 1376–1381. DOI: 10.1097/MPA.0000000000001930
11. Redondo M.J., Hagopian W.A., Oram R. et al. The clinical consequences of heterogeneity within and between different diabetes types. Diabetologia, 2020, vol. 63, pp. 2040–2048. DOI: 10.1007/s00125-020-05211-7
12. Shivaprasad C., Aiswarya Y., Kejal S. et al. Comparison of CGM-derived measures of glycemic variability between pancreatogenic diabetes and type 2 diabetes mellitus. Journal of diabetes science and technology, 2021, vol. 15 (1), pp. 134–140. DOI: 10.1177/1932296819860133
13. Tarasova Zh.S., Bordin D.S., Kileynikov D.V. et al. Pancreatogenic diabetes mellitus: the view of an endocrinologist and gastroenterologist. Effektivnaya farmakoterapiya, 2020, vol. 16 (15), pp. 92–101 (in Russ.).
14. Pandol S.J., Forsmark C.E. Consortium for the study of chronic pancreatitis, diabetes, and pancreatic cancer: achievements and future directions. Current Opinion in Gastroenterology, 2021, vol. 37 (5), pp. 486–490. doi: 10.1097/MOG.0000000000000765
15. Vonderau J.S., Desai C.S. Type 3c: Understanding pancreatogenic diabetes. JAAPA, 2022, vol. 35 (11), pp. 20–24. DOI: 10.1097/01.JAA.0000885140.47709.6f
16. Lomakina E.Yu., Taratina O.V., Belousova E.A. Chronic pancreatitis and diabetes mellitus: a review of the literature. Al’manakh klinicheskoy meditsiny, 2019, vol. 47, no. 6, pp. 525–534 (in Russ.).
17. Johnston P.C., Thompson J., Mckee A. et al. Diabetes and chronic pancreatitis: considerations in the holistic management of an often neglected disease. Journal of Diabetes Research, 2019, vol. 2019. DOI: 10.1155/2019/2487804
18. Goodarzi M.O., Nagpal T., Greer P. et al. Genetic risk score in diabetes associated with chronic pancreatitis versus type 2 diabetes mellitus. Clinical and translational gastroenterology, 2019, vol. 10 (7). DOI: 10.14309/ctg.0000000000000057
19. Eibl G., Rozengurt E. Metformin: review of epidemiology and mechanisms of action in pancreatic cancer. Cancer and Metastasis Reviews, 2021, vol. 40 (3), pp. 865–878. DOI: 10.1007/s10555-021-09977-z